Page 139 - MEMOCiberesp014-ENG

• Technological Platform on Nanomedicine .
The in vivo experimentation unit allows data to be obtained on the systemic behaviour of biomarkers (bio- distribution, pharmacokinetics, pharmacodynamics, toxicity and therapeutic activity) using imaging techni- ques, combining invasive and non-invasive procedures .
This unit also enables nanomedicine-based therapies to be tested on conventional cell lines and primary cultures (loss and gain of function experiments and gene expression analysis, as well as studying control of expression at various levels: transcriptional [gene transfection, inducible systems], posttranscriptional [RNAi] and at the protein level [antagonists and antibody neutralization]) .
Most relevant scientific articles
• alana l., sese M., CanoVas V., Punyal y., FernÁnDez y., aBasolo i. et al . Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression . Molecular Cancer . 2014;13(1) .
• CanDiota a.P., aCosta M., siMoes r.V., DelgaDo-goni t., loPe-PieDraFita s., irure a. et al . A new ex vivo method to evaluate the performance of candidate MRI contrast agents: A proof-of-concept study . Journal of Nano- biotechnology . 2014;12(1) .
• MouraDoV D., sloggett C., Jorissen r.n., loVe C.g., li s., Burgess a.W. et al . Colorectal cancer cell li- nes are representative models of the main molecular subtypes of primary cancer . Cancer Research . 2014;74(12):3238-3247 .
• Mateo F, MeCa-Cortés o, Celià-terrassa t, FernÁnDez y, aBasolo i, sÁnChez-CiD l et al . SPARC mediates me- tastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations .Molecular cancer . 2014;13:237 .
• roDrigues P, MaCaya i, BazzoCCo s, Mazzolini r, anDretta e, DoPeso h et al . RHOA inactivation enhances Wnt signalling and promotes colorectal cancer .Nature communications . 2014;5:5458 .
Highlights
The group on Drug Delivery and Targeting seeks two main goals; on the one hand, the identification of new disease biomarkers and therapeutic targets, with special focus on cancer, and on the other hand, the deve- lopment of new drug delivery and targeting approaches for clinical applications . Among our projects are a new EuroNanoMed II project focused in nanomedicine applications involving SME’s in which animal models are being used for preclinical validation of new therapies directed against tumor cells (DiamESTar), and four additional projects, two of them from Marató TV3 (Nanofabry: focused in drug delivery systems for the Fa- bry disease and Pentri: for active targeting against cancer stem cells), an INNPACTO (also involving industry) granted in 2013 and a RETOS project recently approved together with SMEs and focused into scale-up and preclinical validation of drug delivery systems . Additional National grants were also obtained . Several in vitro and in vivo cancer models have been generated by the group for preclinical testing of nanomedicines, inclu- ding the generation of specific cancer stem cell models . Two patents from the group are in National Fases . Dr Schwartz Jr is also member of the Nanomedicine Spanish Platform (NanomedSpain), the “European Platform for Nanomedicine” and the “European Fundation for Clinical Nanomedicine” (CLINAM) . Dr Schwartz has also been appointed as Scientific Advisor by the Southern Denmark University of the excellence center NANOCAN for Nanomedicine andacts as an external evaluator of the Swedish Research Council and associate editor of Nanomedicine NMB (FI:6,9) . Further, Dr Schwartz’s group published papers in top science journals in 2014 .
Institution: Fundación Hospital Universitario Vall D´hebron - Institut De Recerca (VHIR) Contact: Hospital Valle Hebron . Passeig Vall d’Hebron, 119-129 · 08035 Barcelona Tel .: (+34) 93 489 40 53 · E-mail: simo .schwartz@vhir .org · Website: http://www .cibbim .eu/
www .ciber-bbn .es 139